NS5B: RNA-directed RNA polymerase
Protein in Hepacivirus hominis that 20 drugs act on.
- Drugs that act on it: 20
- Approved: 3
- In phases 1 to 3: 17
- Sponsors: 11
Who is on it, and how far along
Every drug ChEMBL records acting on NS5B, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 20
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
| SofosbuvirBoxed warning | Approved | Gilead Sciences | Small molecule | Inhibitor | 21 |
| RibavirinBoxed warning | Approved | Bausch Health | Small molecule | Inhibitor | 7 |
| Dasabuvir | Approved | AbbVie | Small molecule | Inhibitor | 0 |
| Beclabuvir | Phase 3 | Bristol-Myers Squibb | Small molecule | Negative allosteric modulatorRNA-directed RNA polymerase negative allosteric modulator | 0 |
| Deleobuvir | Phase 3 | Boehringer Ingelheim Pharmaceuticals | Small molecule | Inhibitor | 0 |
| Filibuvir | Phase 3 | Pfizer | Small molecule | Inhibitor | 0 |
| ABT-072 | Phase 2 | AbbVie | Small molecule | Inhibitor | 0 |
| Adafosbuvir | Phase 2 | Johnson & Johnson | Small molecule | Inhibitor | 0 |
| Balapiravir | Phase 2 | Roche | Small molecule | Inhibitor | 0 |
| BMS-986094 | Phase 2 | Bristol-Myers Squibb | Small molecule | Inhibitor | 0 |
| Lomibuvir | Phase 2 | Vertex Pharmaceuticals | Small molecule | Negative allosteric modulatorRNA-directed RNA polymerase negative allosteric modulator | 0 |
| Mericitabine | Phase 2 | Roche | Small molecule | Inhibitor | 0 |
| Nesbuvir | Phase 2 | Wyeth is now a wholly owned subsidiary of Pfizer | Small molecule | Inhibitor | 0 |
| PSI-352938 | Phase 2 | Gilead Sciences | Small molecule | Inhibitor | 0 |
| Radalbuvir | Phase 2 | Gilead Sciences | Small molecule | Inhibitor | 0 |
| Setrobuvir | Phase 2 | Roche | Small molecule | Inhibitor | 0 |
| Tegobuvir | Phase 2 | Gilead Sciences | Small molecule | Inhibitor | 0 |
| TMC-647055 | Phase 2 | Merck & Co. (MSD) | Small molecule | Inhibitor | 0 |
| Uprifosbuvir | Phase 2 | Merck & Co. (MSD) | Small molecule | Inhibitor | 0 |
| Valopicitabine | Phase 2 | Merck & Co. (MSD) | Small molecule | Inhibitor | 0 |
| AI-Powered Hepatitis C Single-Encounter Test-and-Treat | Sofosbuvir | Phase 4 | Not yet recruiting | Patrick Grace | Aug 28, 2026 |
| Treatment of CKD Patients With HCV | Ribavirin, Sofosbuvir | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | Aug 18, 2026 |
| Sofosbuvir/Velpatasvir/Voxilaprevir Salvage Therapy in Hepatitis C Patients Who Relapsed After DAA Treatment | Sofosbuvir | — | Active, not recruiting | Xiangya Hospital of Central South University | May 4, 2026 |
| Combating Related Epidemics in HCV | Sofosbuvir | Phase 4 | Not yet recruiting | Duke University | Apr 30, 2026 |
| SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF | Sofosbuvir | — | Active, not recruiting | Center of target therapy | Jan 5, 2026 |
| Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy | Sofosbuvir | Phase 4 | Not yet recruiting | ANRS, Emerging Infectious Diseases | Aug 1, 2025 |
| C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV | Sofosbuvir | Phase 3 | Active, not recruiting | Atea Pharmaceuticals, Inc. | Jun 25, 2025 |
| Implementing Low-Barrier HCV Treatment in a Jail Setting | Sofosbuvir | Phase 4 | Recruiting | Lifespan | May 1, 2025 |
| UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF | Ribavirin | Phase 2 | Recruiting | Liverpool School of Tropical Medicine | Mar 6, 2025 |
| Assessing Antiviral Treatments in Early Symptomatic RSV | Ribavirin | Phase 2 | Recruiting | University of Oxford | Jul 5, 2024 |
| LAssa Fever Adjunct Treatment With DEXamethasone | Ribavirin | Phase 2 | Recruiting | Bernhard Nocht Institute for Tropical Medicine | Jan 25, 2024 |
| ISTH/ANRS 0409s INTEGRATE Lassa Fever Study | Ribavirin | Phase 2 / Phase 3 | Recruiting | Irrua Specialist Teaching Hospital | Jan 18, 2024 |
| The Efficacy of Vosevi in Treating DAA-experienced Patients | Ribavirin | — | Recruiting | The Third Affiliated Hospital of Guangzhou Medical University | Dec 22, 2023 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | Ribavirin | — | Recruiting | Duke University | Feb 20, 2020 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4296320, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets